UnitedHealth Group (UNH)‘s stock has surged over 37% since August, marking a sharp rebound after a nearly year-long slump. This rally gained significant momentum from a powerful catalyst: a new investment by Warren Buffett’s Berkshire Hathaway.
Buffett’s moves are closely watched as a barometer of value. His stake signals that the famed investor, with deep insurance industry expertise, may see deep value in UnitedHealth following its substantial decline. When the news broke, the stock traded at a price-to-earnings multiple around 10. Even after the rally, with a P/E of 17, many investors still find it attractive.
The market enthusiasm isn’t fueled by celebrity alone. Wall Street analysts are providing fundamental validation. On Wednesday, Wolfe Research analyst Justin Lake raised his price target on UnitedHealth by 14%, from $330 to $375 per share, maintaining an Outperform rating.
This upgrade is grounded in a reassessment of the company’s core segments. Lake is optimistic that the foundational UnitedHealthcare insurance business can improve its margins. He also expects meaningful growth from the Optum health services and technology unit, providing a fundamental rationale beyond short-term sentiment.
Despite the positive news, potential investors must weigh persistent challenges. A Department of Justice investigation into billing practices remains unresolved. Costs are rising in its Medicare Advantage business, and the company is strategically exiting some Advantage markets to improve profitability.
Recent earnings offered a glimmer of improvement. Third-quarter revenue grew 12% year-over-year to $113.2 billion. The company also modestly raised its full-year EPS guidance. Analyst consensus projects approximately 9% EPS growth by 2026.
Berkshire’s investment and the analyst upgrade have jointly spotlighted UnitedHealth’s potential value. However, the path to recovery isn’t guaranteed.
For investors, this serves as a notable signal: a leading industry stock, trading in value territory, is now getting a closer look from both sophisticated money and fundamental research. The ultimate decision hinges on one’s conviction in the company’s ability to navigate current headwinds and the patience to wait for a turnaround.
Following a master investor isn’t about simple imitation—it’s about understanding the logic and aligning it with your own risk tolerance.
